UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,393	08/15/2006	Henri Rainer Nordlund	3516-1010	6414
466 YOUNG & TH	7590 09/21/201 OMPSON	EXAMINER		
209 Madison St Suite 500		MONSHIPOURI, MARYAM		
Alexandria, VA	. 22314	ART UNIT	PAPER NUMBER	
			1656	
			NOTIFICATION DATE	DELIVERY MODE
			09/21/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DocketingDept@young-thompson.com

		Application No.	Applicant(s)			
Office Action Summary		10/579,393	NORDLUND ET AL.			
		Examiner	Art Unit			
		MARYAM MONSHIPOURI	1656			
Period fo	The MAILING DATE of this communication or Reply	appears on the cover sheet with the	correspondence address			
A SH WHIC - Exter after - If NC - Failu Any r	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication of period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNICATION R 1.136(a). In no event, however, may a reply be to the control of	ON. imely filed m the mailing date of this communication. IED (35 U.S.C. § 133).			
Status						
1)🖂	Responsive to communication(s) filed on 2	<u>6 July 2010</u> .				
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.					
3)□						
	closed in accordance with the practice und	er <i>Ex part</i> e <i>Quayle</i> , 1935 C.D. 11, 4	l53 O.G. 213.			
Dispositi	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) 47-53 and 55-67 is/are pending in 4a) Of the above claim(s) 53 and 55 is/are value (s) is/are allowed. Claim(s) 26-52 and 56-67 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction are	withdrawn from consideration.				
Applicati	on Papers					
10)	The specification is objected to by the Exan The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the cortheoath or declaration is objected to by the	accepted or b) objected to by the the drawing(s) be held in abeyance. So rection is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority ι	ınder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
Attachmen		л П	(DTO 440)			
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>8/15/06</u> .	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date			

Applicant's response to restriction letter of 5/26/2010 and supplemental amendment of 7/26/2010 are acknowledged.

Claims 1-46 and 54 are canceled. Claims 47-52 and 56-67 are under examination on the merits. Claims 53 and 55 are hereby withdrawn as drawn to non-elected invention.

On 7/17/2010 the examiner called up applicant (Mr. H. James Voeller) to propose amending some claims in order to push claims closer to allowance. On 7/26/2010 applicant filed in a supplemental amendment, which is currently under examination.

The inventions (a) to (j), as shown in the restriction letter of 9/2/2009, are hereby withdrawn.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 47-52, 56-58, 64-67 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase "circularly permuted" in the preamble of claim 47 appears to be redundant because each monomer recited has to be circularly permuted. Applicant is advised to delete said phrase from preamble of base claim 47. Claims 48-52 ,56-58 and 64-67 are merely rejected for depending from a rejected base claim.

Claim 47-52, 56-58, 64-67 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In claim 47, last paragraph, the term "second" appears to lack antecedent basis because there is no "first" to be found.

Applicant is advised to recite the term "first" into the last paragraph of said claim or possibly amend claim 47. Claims 48-52 and 56-58 and 64-67 are merely rejected for depending from a rejected base claim.

Claim 48 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The phrase " in the circularly permuted avidin" does not seem to add anything to the scope of the claim and is confusing. Appropriate correction is required.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 47-52, 56-67 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The dual-chain avidin (dcAvd) of claim 47 (and its dependent claims 48-52, 56-58 and 64-67), and the dual chain pseudo-

Application/Control Number: 10/579,393

Art Unit: 1656

tetrameric avidin of claim 59 (and its dependent claims 60-63) are directed to products which lack adequate structural description.

Page 4

The court of Appeals for the Federal Circuit has recently held that such a general definition does not meet the requirements of 35 U.S.C. 112, first paragraph. " A written description of an invention involving chemical genus, like a description of a chemical species, requires a precise definition, such as be structure, formula {or} chemical name, of the claimed subject matter sufficient to distinguish it from other materials." *University* of California v. Eli Lilly and Co., 1997 U.S. App. LEXIS 18221, at *23, quoting Fiers v. Revel, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993). The court held that "in claims involving chemical materials, generic formulae usually indicate with specificity what generic claims encompass. One skilled in the art can distinguish such a formula fro others and can identify many of the species that the claims encompass, accordingly, such a formula is normally an adequate description of the claimed genus. In claims to genetic material, however, a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA," without more, is not an adequate written description of the genus because it does not distinguish it from others. One skilled in the art therefore cannot, as one can do with a fully described genus visualize the identity of the members of the genus". Here, in the case of claim 47 (and its above mentioned dependent claims) applicant is claiming products by what they do rater than what they do rather than what they structurally. In claim 59 (and its above mentioned claims) this problem is more serious because there is neither function nor structure to be found and the claim is independent. Therefore said claims fail to meet the requirements of 112 first paragraph.

Application/Control Number: 10/579,393 Page 5

Art Unit: 1656

Applicant is referred to the revised interim guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov.

Double Patenting

Claim 56 is objected to under 37 CFR 1.75 as being a substantial duplicate of claim 47. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). In claim 47, it has already been recited that avidin monomers may be joined together or via a linker. It is unclear how the scope of claim 56, which recites the term "spacer" instead of "linker" is different than its base claim 47. There appears to be no difference between "spacer" and "linker" in the specification.

Appropriate clarification is required.

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARYAM MONSHIPOURI whose telephone number is (571)272-0932. The examiner can normally be reached on Tues.-Fri., from 7:00 a.m to 5:30 p.m..

Application/Control Number: 10/579,393 Page 6

Art Unit: 1656

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Rao Munjunath can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Maryam Monshipouri/

Primary Examiner, Art Unit 1656
